Marvel Biosciences Corp is Shariah compliant. The company’s financials pass just one standard and fail in the other four.
Ad
MRVL – Marvel Biosciences Corp
Compliant
★☆☆☆☆
- Biotechnology & Medical Research
- Toronto Venture Exchange
- July 16, 2022
$2,798,412
Market cap
-
Revenue Growth
-
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 0% | ✓ |
| Non-Compliant Assets ÷ MC | % |
S&P
S&P ✗
| Debt ÷ 36 mo MC | 0% | ✓ |
| Cash ÷ 36 mo MC | 86.23% | ✗ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✗
| Debt ÷ 24 mo MC | 0% | ✓ |
| Cash ÷ 24 mo MC | 64.63% | ✗ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 0% | ✓ |
| Cash ÷ Assets | 96.96% | ✗ |
| Cash&AR ÷ Assets | 96.96% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 0% | ✓ |
| Cash ÷ Assets | 96.96% | ✗ |
| Cash&AR ÷ Assets | 96.96% | ✗ |
Ad
N/A
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Total Analysts: 0
Company Profile
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage biotechnology company. The Company is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The Company has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Ad
Responses